Cytokinetics (CYTK) shares outstanding

Shares outstanding · fiscal 2025
120.10M

Cytokinetics (CYTK) had 120.10M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 7.3% higher than the 111.98M of fiscal 2024. Figures as of 18 Nov 2026, 12:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Shares outstanding, fiscal 2025
120.10M
Change on fiscal 2024
+7.3%
Growth, 5 years
+13.2% a year
Growth, 10 years
+12.0% a year
Highest on record
120.10Mfiscal 2025
Lowest on record
9.66Mfiscal 2009
Fiscal years on record
142009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Cytokinetics shares outstanding, in more detail

The market data feed counts 139.30M shares outstanding today.

Over the five fiscal years to 2025 the diluted share count grew at a compound 13.2% a year; over ten years the rate was 12.0% a year. Across the 14 fiscal years on record (2009–2025), the highest was 120.10M in fiscal 2025 and the lowest 9.66M in fiscal 2009.

History · 14 fiscal years

Shares outstanding by fiscal year

Cytokinetics shares outstanding, year by year

Cytokinetics (CYTK) shares outstanding by fiscal year
Fiscal yearShares outstandingChangeYear ended
2025120.10M 7.3% up
2024111.98M 16.0% up
202396.52M 7.5% up
202289.83M 16.8% up
202176.90M 19.0% up
202064.61M—
201749.40M 16.1% up
201642.56M 9.7% up
201538.81M 8.7% up
201435.71M—
201218.11M 53.4% up
201111.80M 10.3% up
201010.69M 10.7% up
20099.66M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.

How to read it

A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.

Shares outstanding at health care companies of similar size

Shares outstanding of Cytokinetics and comparable companies
CompanyShares outstandingFiscal year
Alkermes ALKS168.74M2025
PACS Group PACS156.70M2025
ImmunityBio IBRX919.86M2025
Cytokinetics CYTK120.10M2025
ABIVAX ABVX69.53M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CYTK

Cytokinetics, figure by figure

Cytokinetics (CYTK) overview: price, valuation and scorecardAll health care companies by market value

Cytokinetics shares outstanding: questions and answers

How many shares does Cytokinetics have?

Cytokinetics (CYTK) had 120.10M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 7.3% higher than the 111.98M of fiscal 2024. The market data feed counts 139.30M shares outstanding today.

What is the growth rate of Cytokinetics's diluted share count?

Over the five fiscal years to 2025 the diluted share count grew at a compound 13.2% a year; over ten years the rate was 12.0% a year.

What are the highest and lowest diluted share count figures on record for Cytokinetics?

Across the 14 fiscal years on record (2009–2025), the highest was 120.10M in fiscal 2025 and the lowest 9.66M in fiscal 2009.

How is Cytokinetics's diluted share count calculated?

The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For Cytokinetics it is on record here for 14 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cytokinetics (CYTK) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/CYTK/shares-outstanding

Underlying data: the company's filings with the SEC and Yahoo Finance.